NTRK3 and thyroid gland carcinoma: Similarly, Yoshihara and colleagues found targetable kinase mutations in 4.9% of patients with thyroid cancer and RET fusions, 1% of patients with thyroid cancer with NTRK1 fusions, and 1.8% of patients with thyroid cancer with NTRK3 fusions (11).